Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment

Abstract

(Cell Reports 32, 107873-1–107873-11.e1–e4; July 7, 2020) In the originally published version of this paper, Figure 3A contained some incorrectly labeled dendritic cell populations. The figure has been updated, and the corrected figure now appears here and with the paper online. The authors regret this error.Figure 3Cxcl9+ Monocyte-Derived TAMs Predict Responsiveness to Anti-PD-L1 Therapy (Original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab TreatmentQu et al.Cell ReportsJuly 07, 2020In BriefQu and colleagues combine a bilateral tumor model approach with scRNA-seq to identify immune cell types that predict response to the immune checkpoint inhibitor avelumab (anti-PD-L1). A Cxcl9-expressing, tumor-associated myeloid population is present in tumors before treatment and predicts a favorable outcome in pre-clinical and clinical studies. Full-Text PDF Open Access